Evidence map›Paper›PMID 37676958›Full record

ArticleScience (New York, N.Y.)2023

Cross-coupling by a noncanonical mechanism involving the addition of aryl halide to Cu(II).

Connor P Delaney, Eva Lin, Qinan Huang, Isaac F Yu, Guodong Rao, Lizhi Tao, Ana Jed, Serena M Fantasia, Kurt A Püntener, R David Britt and 1 more

Open access · greenAbstract read
In one paragraph

Article in Science (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Efficient Aminations of Aryl Halides by a Cu(II) Catalyst.Journal of the American Chemical Society · 2025
    Article
  14. Article
  15. Article
  16. Room-Temperature Copper-Catalyzed Etherification of Aryl Bromides.Angewandte Chemie (International ed. in English) · 2024
    Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Connor P DelaneyCollege of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-6885-6011
Eva LinCollege of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0009-0009-7562-1761
Qinan HuangCollege of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-5185-1097
Isaac F YuCollege of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0001-9659-2204
Guodong RaoDepartment of Chemistry, University of California, Davis, Davis, CA 95616, USA.ORCID 0000-0001-8043-3436
Lizhi TaoDepartment of Chemistry, University of California, Davis, Davis, CA 95616, USA.ORCID 0000-0001-9921-2297
Ana JedCollege of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0009-0005-3210-5581
Serena M FantasiaPharmaceutical Division, Synthetic Molecules Technical Development, Process Chemistry and Catalysis, F. Hoffmann-La Roche, Ltd., Basel, CH-4070, Switzerland.ORCID 0000-0001-6036-6600
Kurt A PüntenerPharmaceutical Division, Synthetic Molecules Technical Development, Process Chemistry and Catalysis, F. Hoffmann-La Roche, Ltd., Basel, CH-4070, Switzerland.
R David BrittDepartment of Chemistry, University of California, Davis, Davis, CA 95616, USA.ORCID 0000-0003-0889-8436
John F HartwigCollege of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-4157-468X
University of California, Berkeley · USRoche (Switzerland) · CHUniversity of California, Davis · USMiller College · US

Funding

Supplement:Spectroscopy Investigations of Metalloenzyme MechanismsR35GM126961 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI R. David Britt · 2018 to 2026
$3.7M
A proposal for the purchase of a new Cu anode Microsource X-ray Diffractometer wiS10RR027172 · NCRR · UNIVERSITY OF CALIFORNIA BERKELEY · PI RAYMOND, KENNETH N · 2010 to 2010
$500k
GPU Computing Cluster for Transformative Public Health driven Molecular ScienceS10OD034382 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI DURKIN, KATHLEEN A · 2023 to 2023
$491k
Acquisition of a Cryoprobe and Related Accessories for a 600 MHz NMR Spectrometer to Support Health Research Activities at the University of California, BerkeleyS10OD024998 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI HARTWIG, JOHN F · 2018 to 2018
$265k
Feeding Machine Learning Algorithms with Mechanistic Data to Predict Outcomes of Copper-Catalyzed CouplingsF32GM140550 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI DELANEY, CONNOR · 2021 to 2022
$120k
NCRR NIH HHS S10 RR027172NIGMS NIH HHS F32 GM140550NIGMS NIH HHS R35 GM126961NIH HHS S10 OD024998NIH HHS S10 OD034382
6 · The paper itself

Abstract

Copper complexes are widely used in the synthesis of fine chemicals and materials to catalyze couplings of heteroatom nucleophiles with aryl halides. We show that cross-couplings catalyzed by some of the most active catalysts occur by a mechanism not previously considered. Copper(II) [Cu(II)] complexes of oxalamide ligands catalyze Ullmann coupling to form the C-O bond in aryl ethers by concerted oxidative addition of an aryl halide to Cu(II) to form a high-valent species that is stabilized by radical character on the oxalamide ligand. This mechanism diverges from those involving Cu(I) and Cu(III) intermediates that have been posited for other Ullmann-type couplings. The stability of the Cu(II) state leads to high turnover numbers, >1000 for the coupling of phenoxide with aryl chloride electrophiles, as well as an ability to run the reactions in air.

Identifiers

PMID37676958
PMCPMC11723509
OpenAlexW4386523659

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.